AstraZeneca Shares Plunge 9% After Wainua Heart Drug Fails Phase 3 Trial
AZN•AZN•AZN•AZN•AstraZeneca’s heart drug Wainua, developed with Ionis, failed to meet the main goal of reducing cardiovascular deaths and recurrent heart problems in a late-stage trial. Shares plunged about 9%, dragging the FTSE 100 lower at the open.
Wainua, AstraZeneca’s antisense therapy developed with Ionis, failed its Phase 3 study by not achieving the primary endpoint of reducing cardiovascular deaths and recurrent heart events, dimming approval prospects for the drug.
AstraZeneca shares tumbled roughly 9% on the news, contributing to a lower FTSE 100 opening as investors reassessed the firm's pipeline value.
The setback forces AstraZeneca to reevaluate its cardiovascular pipeline strategy, potentially reallocating resources to other late-stage assets and reassessing future earnings forecasts.
Finance
